Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
AffiliationDepartment of Internal Medicine, Rush University Medical Center, Chicago, IL, USA
MetadataShow full item record
AbstractUpregulated expression and aberrant activation of the epidermal growth-factor receptor (EGFR) are found in lung cancer, making EGFR a relevant target for non-small-cell lung cancer (NSCLC). Treatment with anti-EGFR monoclonal antibodies (mAbs) is associated with modest improvement in overall survival in patients with squamous cell lung cancer (SqCLC) who have a significant unmet need for effective treatment options. While there is evidence that using EGFR gene copy number, EGFR mutation, and EGFR protein expression as biomarkers can help select patients who respond to treatment, it is important to consider biomarkers for response in patients treated with combination therapies that include EGFR mAbs.
CitationPredictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. 2018, Ann Oncol
JournalAnnals of Oncology